DataMEDS AI Terminates Second Amended Letter of Intent With Datavault AI, Ending Share Issuance

DataMEDS AI terminated its Second Amended and Restated letter of intent with Datavault AI and other parties, ending related share issuance with no fees or obligations owed. Stock Titan reported the termination on November 3, 2026.

DataMEDS Ends the October 19 Letter of Intent

DataMEDS AI, which trades on Nasdaq under MEDS, terminated the Second Amended and Restated letter of intent dated October 19, 2026 with Datavault AI, Data Health Partners subsidiary REBOOT Health AI, EOS Technology Holdings, Scilex Holding Company and HealthBridge Advisors. The letter of intent covered the in-license or acquisition of IP in exchange for DataMEDS common stock, and DataMEDS cited market conditions for the termination.

DataMEDS said it does not owe any fees or obligation as a result of the termination and will no longer issue any shares related to the letter of intent. The company confirmed that its exclusive license with REBOOT for the management of GLP-1 users, dated October 13, 2026, remains in full force and effect.

DataMEDS also confirmed that the Datavault AI agreement for the PharmacyChain manufacturer-to-patient blockchain-enabled smart contracts remains in full force and effect under terms dated November 24, 2025. No shares of DataMEDS were issued to Datavault in connection with that agreement.

DataMEDS AI, formerly Wellgistics Health, is a Tampa, Florida-based healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform. The company's own announcement describes its pharmacy-related Corexa Health subsidiary and its ownership of Helomics Corporation, a Pittsburgh-based clinical molecular diagnostics laboratory.

Datavault AI's Funding and Contract Figures

According to akta.pro company records, Datavault AI has nine funding rounds on record and total funding of $392.1 million, with its last round dated May 3, 2026. The same records list a May 2026 post-IPO equity round of $60 million and a September 2025 post-IPO debt round of $150 million led by Scilex Holding Company.

The records also list $800 million in tokenization contracts signed during 2026 year to date, reported alongside first-quarter 2026 results, and a $750 million figure for tokenization contracts in the first quarter of 2026 with $77 million in associated fees.

Earlier Datavault AI Moves Before the Termination

On October 14, 2026, AETOSWire reported that Datavault AI signed a non-binding letter of intent to acquire a 19.9% equity stake in DataMEDS AI in exchange for an expanded technology license. On October 15, 2026, TradingView reported that Datavault AI amended its $25.03 million convertible promissory note with Streeterville Capital, setting a $0.0632 Nasdaq conversion floor.

On October 30, 2026, American Banking and Market News reported that Maxim Group lowered its rating on Datavault AI to Hold from Buy.

What Comes Next for the Remaining Agreements

The exclusive license with REBOOT for GLP-1 user management dated October 13, 2026 and the PharmacyChain smart contract agreement dated November 24, 2025 remain in effect, according to DataMEDS.